• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by ImageneBio Inc.

    3/10/26 9:21:04 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMA alert in real time by email
    S-8 1 d107848ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 10, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    IMAGENEBIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   81-1697316

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    12526 High Bluff Drive, Suite 345

    San Diego, CA 92130

    (858) 345-6265

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

    ImageneBio, Inc. 2025 Equity Incentive Plan

    ImageneBio, Inc. 2025 Employee Stock Purchase Plan

    ImageneBio, Inc. 2025 Equity Inducement Plan

    (Full title of the plans)

    Kristin Yarema, Ph.D.

    Chief Executive Officer

    12526 High Bluff Drive, Suite 345

    San Diego, CA 92130

    (858) 345-6265

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Thomas A. Coll, Esq.

    Asa M. Henin, Esq.

    Brittany K. Wightman, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, CA 92121

    (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by ImageneBio, Inc. (the “Registrant”) for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans are effective. The Registrant previously registered its shares of common stock, par value $0.001 per share (the “Common Stock”), for issuance under the Registrant’s 2025 Equity Incentive Plan (the “2025 Plan”), the Registrant’s 2025 Employee Stock Purchase Plan (the “ESPP”) and the Registrant’s 2025 Equity Inducement Plan (the “Inducement Plan”) under the Registrant’s Registration Statement on Form S-8 (the “Prior Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) on November  12, 2025 (File No. 333-291449). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference, except that the provisions contained in Part II of such Prior Registration Statement are modified or supplemented, as the case may be, as set forth in this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Certain Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated by reference to this Registration Statement:

     

      (a)

    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 10, 2026 (the “2025 Annual Report”);

     

      (b)

    the Registrant’s Current Report on Form 8-K filed with the Commission on February 17, 2026; and

     

      (c)

    the description of the Registrant’s Capital Stock filed as Exhibit 4.4 to the 2025 Annual Report.

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the Commission), prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

    Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits.

     

    Exhibit
    No.
       Exhibit Description
      4.1    Fifth Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the Commission on March 30, 2021).
      4.2    Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of the Registrant, dated July  25, 2025 (Stock Split Amendment) (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.  001-40287) filed with the Commission on July 29, 2025).
      4.3    Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of the Registrant, dated July  25, 2025 (Name Change Amendment) (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No.  001-40287) filed with the Commission on July 29, 2025).
      4.4    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the Commission on March 30, 2021).
      5.1    Opinion of Cooley LLP.
     23.1    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
     23.2    Consent of Cooley LLP (included in Exhibit 5.1).
     24.1    Power of Attorney (included on the signature page to this Registration Statement).
     99.1    The Registrant’s 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-290108) filed with the Commission on September 8, 2025).
     99.2    Forms of Option Award Notice, Option Agreement and Notice of Exercise under the Registrant’s 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.21 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the Commission on July 29, 2025).
     99.3    Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under the Registrant’s 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the Commission on July 29, 2025).
     99.4    The Registrant’s 2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-290108) filed with the Commission on September 8, 2025).
     99.5    The Registrant’s 2025 Equity Inducement Plan and Forms of Stock Option Grant Notice, Option Agreement, and Notice of Exercise and Forms of RSU Grant Notice and RSU Agreement thereunder (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40287) filed with the SEC on August 1, 2025).
    107.1    Filing Fee Table.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on the 10th day of March 2026.

     

    IMAGENEBIO, INC.
    By:   /s/ Kristin Yarema
    Name:   Kristin Yarema, Ph.D.
    Title:   Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kristin Yarema, Ph.D. the individual’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or their substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Kristin Yarema

    Kristin Yarema, Ph.D.

      

    Chief Executive Officer and Director

    (Principal Executive Officer and Interim Principal Financial Officer)

      March 10, 2026

    /s/ Erin Butler

    Erin Butler

      

    Senior Vice President, Finance and Administration

    (Principal Accounting Officer)

      March 10, 2026

    /s/ Jonathan Jian Wang

    Jonathan Jian Wang, Ph.D., MBA

       Chair of the Board   March 10, 2026

    /s/ David P. Bonita

    David P. Bonita, M.D.

       Lead Independent Director   March 10, 2026

    /s/ Joseph P. Slattery

    Joseph P. Slattery

       Director   March 10, 2026

     

    Get the next $IMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMA

    DatePrice TargetRatingAnalyst
    11/25/2025$2.00Underperform
    Wedbush
    10/24/2025$30.00Outperform
    Leerink Partners
    More analyst ratings

    $IMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

    SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company Highlights The IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis (AD) is ongoing at North American sites; the study began enrolling in mid-2025 with topline data expected in 2027. A recent blinded safety review showed a favorable emerging tolerability profile consistent with previous IMG-007 patient experience.The Company has submitted a protocol amendment intended to expand the number and exposure range of dosing regim

    3/10/26 8:00:00 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio to Participate in Leerink Global Healthcare Conference

    SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida. Fireside Date: Tuesday, March 10Time: 3:00pm ESTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, IMG-007, is a receptor targe

    2/26/26 8:00:00 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $IMA
    SEC Filings

    View All

    SEC Form S-8 filed by ImageneBio Inc.

    S-8 - ImageneBio, Inc. (0001835579) (Filer)

    3/10/26 9:21:04 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by ImageneBio Inc.

    10-K - ImageneBio, Inc. (0001835579) (Filer)

    3/10/26 8:33:10 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    3/10/26 8:16:24 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Slattery Joseph P bought $95,840 worth of shares (16,000 units at $5.99) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    12/29/25 4:46:28 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Porter-Brown Benjamin

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    2/20/26 4:20:27 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Principal Accounting Officer Butler Erin was granted 22,500 shares, increasing direct ownership by 737% to 25,551 units (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    1/2/26 9:15:55 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Slattery Joseph P bought $95,840 worth of shares (16,000 units at $5.99) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    12/29/25 4:46:28 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush resumed coverage on ImageneBio with a new price target

    Wedbush resumed coverage of ImageneBio with a rating of Underperform and set a new price target of $2.00

    11/25/25 8:27:54 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on ImageneBio with a new price target

    Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00

    10/24/25 9:00:36 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Leadership Updates

    Live Leadership Updates

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations